Physician profile
Thomas J Hamilton
NPI 1871592246
$12,080.80
in general payments reported to CMS, 2019-2025
59 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,767 · 2020: $713 · 2021: $1,448 · 2022: $1,746 · 2023: $1,921 · 2024: $2,088 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,407.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.02 | 2021-2025 | |
| Novo Nordisk INC | $1,069.10 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $975.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $927.49 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $749.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $720.02 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $537.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $497.71 | 2019-2025 | Veozah |
| Allergan, INC. | $488.83 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.65 | 2019-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $413.47 | 2019-2024 | Trintellix |
| Abbott Laboratories | $362.70 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $310.08 | 2019-2025 | Belsomra, Gardasil 9, Verquvo |
| Novartis Pharmaceuticals Corporation | $299.99 | 2019-2025 | |
| Organogenesis INC. | $295.53 | 2019 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.13 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $230.65 | 2022 | |
| Kerecis Limited | $157.18 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Esperion Therapeutics, INC. | $156.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $116.45 | 2019-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.04 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $97.63 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $85.61 | 2019-2025 | Eliquis, Camzyos |
| Teva Pharmaceuticals USA, INC. | $78.86 | 2019-2025 | Austedo Xr, Austedo |
| Eisai INC. | $71.83 | 2021-2022 | |
| Medline Industries LP | $68.71 | 2024 | Medline |
| Saluda Medical Americas, INC. | $66.84 | 2023-2024 | Evoke Scs, Evoke |
| Sanofi-Aventis U.S. LLC | $63.43 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $62.68 | 2024-2025 | Rexulti |
| Corium, LLC | $61.73 | 2023 | Adlarity |
| Dexcom, INC. | $58.89 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Mylan Specialty L.P. | $54.07 | 2019-2024 | Yupelri |
| Viatris Specialty LLC | $53.45 | 2025 | Yupelri |
| Dynavax Technologies Corporation | $53.17 | 2023-2024 | Heplisav-B |
| Vanda Pharmaceuticals INC. | $52.66 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $50.53 | 2021 | |
| Antares Pharma, INC. | $48.09 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Ardelyx, INC. | $45.46 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $45.24 | 2023 | |
| Sanofi Pasteur INC. | $41.96 | 2021-2023 | |
| Integra Lifesciences Corporation | $41.85 | 2020-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Sumitomo Pharma America, INC. | $40.98 | 2024-2025 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $36.51 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $36.34 | 2025 | Belbuca |
| Axsome Therapeutics, INC. | $36.12 | 2024-2025 | Symbravo, Auvelity |
| Idorsia Pharmaceuticals US INC | $34.64 | 2023-2024 | Quviviq |
| Coloplast Corp | $34.48 | 2024 | |
| Exact Sciences Corporation | $33.43 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Clarus Therapeutics INC. | $32.59 | 2021 | |
| Melinta Therapeutics, LLC | $32.51 | 2024-2025 | Orbactiv, Kimyrsa |
| Currax Pharmaceuticals LLC | $28.35 | 2021 | |
| Supernus Pharmaceuticals, INC. | $27.13 | 2021-2025 | Tlando, Xyosted, Qelbree |
| Aroa Biosurgery Incorporated | $20.69 | 2023 | |
| Halozyme INC | $20.12 | 2023 | |
| Genentech USA, INC. | $18.88 | 2019 | |
| Ibsa Pharma INC. | $17.69 | 2023 | Tirosint, Licart |
| Ascensia Diabetes Care US INC. | $15.48 | 2024 | |
| Amneal Pharmaceuticals LLC | $13.61 | 2025 | Unithroid |
| Tolmar, INC. | $13.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.